Pfizer's Ibrance drug slows progression of breast cancer

CHICAGO May 30 (Reuters) - A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.